+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.

Age: 18Years - 85YearsAll GendersPhase 2
224 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of open-label iptacopan in adults with primary IgA nephropathy who have completed earlier clinical trials CLNP023X2203 or CLNP023A2301. This Phase III rollover extension program allows participants to continue treatment while gathering additional data on the drugs effects over time. The study aims to assess the ongoing impact of iptacopan on disease progression until marketing authorization or other specified conditions are met. Participants receive iptacopan capsules at a dose of 200 mg taken orally twice daily. Treatment continues until one of several conditions occurs, including completion of 3 years from the last participants first visit, loss of benefit as judged by the investigator, a change in the drugs benefit-risk profile, need for dialysis or kidney transplant, or drug availability through commercial channels. This open-label design provides continuous access to iptacopan while monitoring long-term effects. During the study, participants undergo safety assessments including monitoring for adverse events, vital sign changes, ECG abnormalities, and laboratory test results from the first dose until 7 days after the last dose. Efficacy evaluations are conducted every 6 months to track kidney function and proteinuria levels. The total participation period may last up to three years, offering detailed data on the drugs long-term safety and clinical impact in primary IgA nephropathy.

Age: 18Years - 100YearsAll GendersPhase 3
161 locations
R

Actively Recruiting

The trial investigates treatments for adults with KRASNRAS and BRAF wild-type recurrent, unresectable, or metastatic colorectal cancer who have previously undergone chemotherapy. It compares how long participants live without disease progression and overall survival when treated with two different combinations of chemotherapy and targeted biological agents. This phase 3 study explores differences in outcomes between the use of amivantamab plus FOLFIRI chemotherapy and cetuximab or bevacizumab plus FOLFIRI chemotherapy. Participants are randomly assigned to one of two groups. One group receives amivantamab together with FOLFIRI, a chemotherapy regimen including 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan. The other group receives either cetuximab or bevacizumab with the same FOLFIRI chemotherapy. Treatments are given in 28-day cycles and continue until disease progression is observed on scans or other stopping criteria are met. During the study, participants undergo regular monitoring including radiographic scans to assess disease status and progression-free survival for up to 2 years and overall survival for over 4 years. Researchers also evaluate tumor response rates, duration and time to response, quality of life through questionnaires, side effects, and laboratory tests. The total study duration may extend up to more than 4 years to thoroughly assess treatment outcomes and safety.

Age: 18Years +All GendersPhase 3
251 locations
R

Actively Recruiting

Researchers are evaluating the anti-tumor effects of amivantamab combined with pembrolizumab and carboplatin compared to pembrolizumab, 5-fluorouracil, and platinum therapy in people with recurrent or metastatic head and neck squamous cell carcinoma HNSCC who have not received prior treatment for their advanced cancer. HNSCC affects tissues in the mouth and throat, and this study focuses on treatment-naive participants in this setting. Participants are assigned to one of two groups one receives pembrolizumab, amivantamab, and carboplatin, while the other receives pembrolizumab, 5-fluorouracil given as a 4-day infusion, and either carboplatin or cisplatin. The study compares these treatment combinations to assess their effects on the cancer over a period of up to about 3 years and 7 months. During the study, participants undergo evaluations including imaging scans to measure tumor response using RECIST criteria, blood tests to monitor drug levels and antibodies, and quality of life questionnaires focused on head and neck symptoms and overall health. Researchers track overall survival, tumor response rates, progression-free survival, duration of response, side effects, and symptom changes. The study involves regular visits for treatment and monitoring throughout the treatment and follow-up period.

Age: 18Years +All GendersPhase 3
205 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of several investigational long-acting antibody treatments, both alone and in combination, for adults with moderately to severely active ulcerative colitis UC. This Phase 2 platform study involves multiple centers and aims to improve treatment options for this condition by comparing different therapies. The study consists of two parts. Part A was an open-label phase assessing safety and early effectiveness of three monotherapies, which completed enrollment in April 2026. Part B is currently enrolling and is a randomized, placebo-controlled phase testing three monotherapies and three combination therapies against placebo. Participants will receive intravenous induction and subcutaneous maintenance treatments, with different dosing regimens evaluated over time. Participants will be monitored through regular assessments including endoscopy and histology to measure disease activity and response. The main outcomes include clinical remission and histologic improvement after 12 weeks, with longer-term remission assessed up to 48 weeks. Safety and efficacy data will be collected throughout, with treatment duration and follow-up determined by study protocol. The total study completion is expected by March 2028.

Age: 18Years - 75YearsAll GendersPhase 2
276 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.

Age: 18Years - 75YearsAll GendersPhase 3
272 locations
R

Actively Recruiting

This trial evaluates the combination of Navlimetostat BMS-986504, pembrolizumab, and chemotherapy compared to placebo with pembrolizumab and chemotherapy in adults with first-line metastatic non-small cell lung cancer having homozygous MTAP deletion. The study is a randomized, double-blind Phase 23 trial sponsored by Bristol-Myers Squibb, aiming to understand treatment benefits in this specific patient group. Participants must have measurable metastatic NSCLC, no prior systemic therapy for metastatic disease, and meet performance status criteria. Participants receive either Navlimetostat plus pembrolizumab and chemotherapy or placebo plus pembrolizumab and chemotherapy. Chemotherapy may include drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel, given on specified days at specified doses. Treatment is administered in the first-line metastatic setting, with detailed dosing and combinations determined by study protocols. Randomization assigns participants to one of multiple arms to compare the investigational combination against placebo. Throughout the study, participants are monitored for progression-free survival up to 2 years and 5 years, overall survival up to 5 years, as well as response rates and safety outcomes including adverse events and laboratory abnormalities. Assessments follow RECIST v1.1 criteria with independent and investigator reviews. Safety monitoring includes tracking serious adverse events and treatment-related side effects up to 90 days after treatment ends. The study duration extends to the primary completion date in August 2031, with ongoing evaluations for up to 5 years post-treatment.

Age: 18Years +All GendersPhase 2Phase 3
321 locations
P

Actively Recruiting

Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
329 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations

1-10 of 25

1